Sofosbuvir/velpatasvir - Gilead Sciences
Alternative Names: Epclusa; GS 5816/sofosbuvir; GS 7977/GS 5816; SOF/VEL; Sofosbuvir/GS 5816; Velpatasvir/sofosbuvirLatest Information Update: 28 Aug 2022
At a glance
- Originator Gilead Sciences
- Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in USA (PO, Granules)
- 22 Jun 2022 Initial efficacy and adverse events data from a phase II trial in Hepatitis C presented at the International Liver Congress (ILC-2022)
- 25 Jun 2021 Gilead Sciences completes a phase III trial for chronic Hepatitis C infection in Japan (PO) (NCT04112303)